Intent-to-treat analyses indicated that , after 6-month maintenance treatment , EX/RP yielded OCD outcomes that were superior to risperidone ( Y-BOCS = 10.95 vs 18.70 ; t40 = 2.76 , P = .009 ) ; more patients randomized to EX/RP met response criteria ( Y-BOCS decrease 25 % : 70 % vs 20 % ; P < .001 ) and achieved minimal symptoms ( Y-BOCS 12 : 50 % vs 5 % ; P < .001 ) .